TNFRSF17 and plasma cell myeloma: Prior to the development of therapies targeting the B-cell maturation antigen (BCMA), patients with multiple myeloma refractory to immunomodulatory agents (IMiD), proteasome inhibitors (PI), and anti-CD38 monoclonal antibodies had limited therapeutic options and an estimated median overall survival (OS) of 5.6–13 months [1, 2].